CovidChloroV1, Main, Corpus, bibRecord, 001980

COVID-19: A Brief Overview of the Discovery Clinical Trial.

Identifieur interne : 001980 ( Main/Corpus ); précédent : 001979; suivant : 001981

COVID-19: A Brief Overview of the Discovery Clinical Trial.

Source :

Pharmaceuticals (Basel, Switzerland) [ 1424-8247 ] ; 2020.

RBID : pubmed:32290348

Abstract

The outbreak of COVID-19 is leading to a tremendous search for curative treatments. The urgency of the situation favors a repurposing of active drugs but not only antivirals. This short communication focuses on four treatments recommended by WHO and included in the first clinical trial of the European Discovery project.

DOI: 10.3390/ph13040065
PubMed: 32290348
PubMed Central: PMC7243102

Links to Exploration step

pubmed:32290348

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">COVID-19: A Brief Overview of the Discovery Clinical Trial.</title>
<author><name sortKey="Vanden Eynde, Jean Jacques" sort="Vanden Eynde, Jean Jacques" uniqKey="Vanden Eynde J" first="Jean Jacques" last="Vanden Eynde">Jean Jacques Vanden Eynde</name>
<affiliation><nlm:affiliation>Formerly head of the Department of Organic Chemistry (FS), University of Mons-UMONS, 7000 Mons, Belgium.</nlm:affiliation>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2020">2020</date>
<idno type="RBID">pubmed:32290348</idno>
<idno type="pmid">32290348</idno>
<idno type="doi">10.3390/ph13040065</idno>
<idno type="pmc">PMC7243102</idno>
<idno type="wicri:Area/Main/Corpus">001980</idno>
<idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">001980</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">COVID-19: A Brief Overview of the Discovery Clinical Trial.</title>
<author><name sortKey="Vanden Eynde, Jean Jacques" sort="Vanden Eynde, Jean Jacques" uniqKey="Vanden Eynde J" first="Jean Jacques" last="Vanden Eynde">Jean Jacques Vanden Eynde</name>
<affiliation><nlm:affiliation>Formerly head of the Department of Organic Chemistry (FS), University of Mons-UMONS, 7000 Mons, Belgium.</nlm:affiliation>
</affiliation>
</author>
</analytic>
<series><title level="j">Pharmaceuticals (Basel, Switzerland)</title>
<idno type="ISSN">1424-8247</idno>
<imprint><date when="2020" type="published">2020</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass></textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">The outbreak of COVID-19 is leading to a tremendous search for curative treatments. The urgency of the situation favors a repurposing of active drugs but not only antivirals. This short communication focuses on four treatments recommended by WHO and included in the first clinical trial of the European Discovery project.</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">32290348</PMID>
<DateRevised><Year>2020</Year>
<Month>09</Month>
<Day>28</Day>
</DateRevised>
<Article PubModel="Electronic"><Journal><ISSN IssnType="Print">1424-8247</ISSN>
<JournalIssue CitedMedium="Print"><Volume>13</Volume>
<Issue>4</Issue>
<PubDate><Year>2020</Year>
<Month>Apr</Month>
<Day>10</Day>
</PubDate>
</JournalIssue>
<Title>Pharmaceuticals (Basel, Switzerland)</Title>
<ISOAbbreviation>Pharmaceuticals (Basel)</ISOAbbreviation>
</Journal>
<ArticleTitle>COVID-19: A Brief Overview of the Discovery Clinical Trial.</ArticleTitle>
<ELocationID EIdType="pii" ValidYN="Y">E65</ELocationID>
<ELocationID EIdType="doi" ValidYN="Y">10.3390/ph13040065</ELocationID>
<Abstract><AbstractText>The outbreak of COVID-19 is leading to a tremendous search for curative treatments. The urgency of the situation favors a repurposing of active drugs but not only antivirals. This short communication focuses on four treatments recommended by WHO and included in the first clinical trial of the European Discovery project.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Vanden Eynde</LastName>
<ForeName>Jean Jacques</ForeName>
<Initials>JJ</Initials>
<AffiliationInfo><Affiliation>Formerly head of the Department of Organic Chemistry (FS), University of Mons-UMONS, 7000 Mons, Belgium.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic"><Year>2020</Year>
<Month>04</Month>
<Day>10</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo><Country>Switzerland</Country>
<MedlineTA>Pharmaceuticals (Basel)</MedlineTA>
<NlmUniqueID>101238453</NlmUniqueID>
<ISSNLinking>1424-8247</ISSNLinking>
</MedlineJournalInfo>
<KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword>
<Keyword MajorTopicYN="N">SARS-CoV-2</Keyword>
<Keyword MajorTopicYN="N">chloroquine</Keyword>
<Keyword MajorTopicYN="N">hydroxychloroquine</Keyword>
<Keyword MajorTopicYN="N">lopinavir/ritonavir</Keyword>
<Keyword MajorTopicYN="N">remdesivir</Keyword>
<Keyword MajorTopicYN="N">repurposing</Keyword>
</KeywordList>
<CoiStatement>The author declares no conflict of interest.</CoiStatement>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year>
<Month>04</Month>
<Day>04</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="revised"><Year>2020</Year>
<Month>04</Month>
<Day>08</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="accepted"><Year>2020</Year>
<Month>04</Month>
<Day>09</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>2020</Year>
<Month>4</Month>
<Day>16</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed"><Year>2020</Year>
<Month>4</Month>
<Day>16</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2020</Year>
<Month>4</Month>
<Day>16</Day>
<Hour>6</Hour>
<Minute>1</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>epublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">32290348</ArticleId>
<ArticleId IdType="pii">ph13040065</ArticleId>
<ArticleId IdType="doi">10.3390/ph13040065</ArticleId>
<ArticleId IdType="pmc">PMC7243102</ArticleId>
</ArticleIdList>
<ReferenceList><Reference><Citation>Antimicrob Agents Chemother. 2014 Aug;58(8):4885-93</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24841273</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>N Engl J Med. 2020 May 7;382(19):1787-1799</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32187464</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>N Engl J Med. 2020 Feb 20;382(8):727-733</Citation>
<ArticleIdList><ArticleId IdType="pubmed">31978945</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Cell Res. 2020 Mar;30(3):269-271</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32020029</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>PLoS Med. 2006 Sep;3(9):e343</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16968120</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Biosci Trends. 2020 Mar 16;14(1):72-73</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32074550</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Emerg Infect Dis. 2004 Feb;10(2):317-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15030704</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>N Engl J Med. 2020 Mar 5;382(10):929-936</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32004427</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Gen Virol. 2014 Mar;95(Pt 3):571-577</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24323636</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Proc Natl Acad Sci U S A. 2020 Mar 24;117(12):6771-6776</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32054787</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>N Engl J Med. 2019 Dec 12;381(24):2293-2303</Citation>
<ArticleIdList><ArticleId IdType="pubmed">31774950</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nat Commun. 2020 Jan 10;11(1):222</Citation>
<ArticleIdList><ArticleId IdType="pubmed">31924756</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nat Microbiol. 2020 Apr;5(4):536-544</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32123347</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Antimicrob Agents Chemother. 2014 Aug;58(8):4875-84</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24841269</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Clin Infect Dis. 2020 Jul 28;71(15):732-739</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32150618</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Infect Dis. 2015 Dec 15;212(12):1904-13</Citation>
<ArticleIdList><ArticleId IdType="pubmed">26198719</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Sci Transl Med. 2017 Jun 28;9(396):</Citation>
<ArticleIdList><ArticleId IdType="pubmed">28659436</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Antimicrob Agents Chemother. 2009 Apr;53(4):1468-75</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19188392</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Med Mal Infect. 2020 Jun;50(4):384</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32240719</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Clin Virol. 2004 Jul;30(3):211-3</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15135736</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Med Virol. 2020 Jun;92(6):556-563</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32104907</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Rheumatol. 1985 Aug;12(4):692-4</Citation>
<ArticleIdList><ArticleId IdType="pubmed">4057189</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>N Engl J Med. 2020 May 7;382(19):1851-1852</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32187463</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Retrovirology. 2015 Jun 18;12:51</Citation>
<ArticleIdList><ArticleId IdType="pubmed">26084487</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Int J Antimicrob Agents. 2020 Jul;56(1):105949</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32205204</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Med Chem. 2006 May 4;49(9):2845-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16640347</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
</PubmedData>
</pubmed>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/CovidChloroV1/Data/Main/Corpus

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001980 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd -nk 001980 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    CovidChloroV1
   |flux=    Main
   |étape=   Corpus
   |type=    RBID
   |clé=     pubmed:32290348
   |texte=   COVID-19: A Brief Overview of the Discovery Clinical Trial.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Corpus/RBID.i   -Sk "pubmed:32290348" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd   \
       | NlmPubMed2Wicri -a CovidChloroV1

This area was generated with Dilib version V0.6.38.
Data generation: Sat May 22 17:02:32 2021. Site generation: Sat May 22 17:06:52 2021

	Serveur d'exploration COVID et hydrochloroquine
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration COVID et hydrochloroquine

COVID-19: A Brief Overview of the Discovery Clinical Trial.

COVID-19: A Brief Overview of the Discovery Clinical Trial.

Source :

Abstract

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki